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S U M M A R Y
Background: Traditionally, pneumonia developing in patients who receive healthcare services in the
outpatient environment has been classiﬁed as community-acquired pneumonia (CAP). However, recent
investigations suggest that this type of infection, known as healthcare-associated pneumonia (HCAP), is
distinct from CAP in terms of its epidemiology, etiology, and risk for infection with multidrug-resistant
(MDR) pathogens.
Methods: A Medline literature review of available clinical studies using the term HCAP was conducted
to determine outcomes compared to CAP and effective empiric treatment strategies.
Results: Analysis of multi-institutional clinical data showed that mortality in hospitalized patients
with HCAP is greater than that in CAP, and patients with HCAP received inappropriate initial empiric
antibiotic treatment more frequently than CAP patients. The bacterial pathogens associated with HCAP
also differed from CAP with potentially MDR Gram-positive and Gram-negative bacteria being more
common in HCAP.
Conclusions: All patients hospitalized with suspected HCAP should be evaluated for their underlying
risk of infection with MDR pathogens. Because HCAP is similar to hospital-acquired pneumonia (HAP),
both clinically and etiologically, it should be treated as HAP until culture data become available.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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In recent years, the traditional distinction between community-
acquired and hospital-acquired infections has become less clear,
with some infections having mixed characteristics of both types.1,2
Pneumonia occurring before hospital admission in patients with
recent contact with the health system has been termed ‘health-
care-associated pneumonia’ (HCAP), and has been proposed as a
new category of respiratory infection that needs a distinct
approach when selecting empiric antibiotic therapy.3–9
Since the publication of the 2005 update of the American
Thoracic Society and Infectious Diseases Society of America (ATS/
IDSA) nosocomial pneumonia guidelines, which incorporated for
the ﬁrst time the concept of HCAP, 12 studies have provided
original data on HCAP.4,6,10–19 On the basis of the published data,
patients with recent or chronic contact with the healthcare system
appear to be at increased risk of infection with multi-drug resistant
(MDR) pathogens.3,4 These pathogens are frequently not covered
by the initial antimicrobial treatment recommended in guidelines* Corresponding author. Tel.: ++1 314 454 8764; fax: ++1 314 454 5571.
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doi:10.1016/j.ijid.2011.04.005for community-acquired pneumonia (CAP).7 Many physicians are
also unaware of the risk factors for HCAP and the clinical relevance
of distinguishing it from CAP.9,20 Since patients classiﬁed as having
HCAP are often heterogeneous, and the studies published on HCAP
sometimes differ in setting and methodology, some authors have
criticized the concept of HCAP.21
Therefore, the aim of this paper is to critically review the
available evidence on HCAP and to propose a summary of
recommendations regarding the deﬁnition of HCAP.
2. Methods
A Medline literature review of available clinical studies using the
term HCAP was conducted to determine outcomes compared to CAP
and to identify risk factors for HCAP. The references of the identiﬁed
citations were also reviewed for additional pertinent studies.
3. Results and discussion
3.1. Deﬁnitions of HCAP: the body of evidence
A correct recognition of risk factors for HCAP is crucial, because
acceptance of a broader deﬁnition of HCAP could potentiallyses. Published by Elsevier Ltd. All rights reserved.
Table 1
Deﬁnitions of HCAP used in different studies according to four criteria
Study [Ref.] Previous hospitalization Hemodialysis; home
infusion therapy
Residence in
a nursing home
or LTCF
Immunosuppression
ATS/IDSA guidelines At least 2 days in the
preceding 90 days
Yes; within 30 days Yes Immunosuppressive disease and/or therapya
Kollef et al. 2005 In the preceding 30 days Yes Yes No
Micek et al. 2007 In the preceding 360 days Yes Yes Corticosteroids (5 mg/day or more), HIV infection,
solid organ or bone marrow transplant, radiation
or chemotherapy for cancer in the past 6 months,
inherited or acquired immunodeﬁciency
Carratala` et al. 2007 At least 2 days in the
preceding 90 days
Yes; within 30 days Yes Intravenous chemotherapy in the 30 days before pneumonia
Webster et al. 2007 At least 2 days in the
preceding 30 days
Yes; within 30 days Yes Intravenous chemotherapy in the 30 days before pneumonia
Shorr et al. 2008 In the preceding 90 days Yes Yes Presence of neutropenia, concurrent use of an oral
corticosteroid (at least 5 days of therapy) or other
immunosuppressive agent, active chemotherapy for
malignancy, or infection with HIV
Venditti et al. 2009 At least 2 days in the
preceding 180 days
Yes; within 30 days Yes Intravenous chemotherapy in the 30 days before pneumonia
Shindo et al. 2009 At least 2 days in the
preceding 90 days
Yes; within 30 days Yes No
Rello et al. 2010 At least 2 days in the
preceding 90 days
Yes; within 30 days Yes Intravenous chemotherapy in the 30 days before pneumonia
Schreiber et al. 2008 In the preceding 90 days Yes; within 30 days Yes Immunosuppressive therapy in the 30 days before pneumonia
Cecere et al. 2010 In the preceding 90 days Yes Yes HIV infection, neutropenia in the past 2 weeks, use of 20 mg
of prednisone per day, or other immunosuppressant drugs
HCAP, healthcare-associated pneumonia; ATS/IDSA, American Thoracic Society/Infectious Diseases Society of America; LTCF, long-term care facility; HIV, human
immunodeﬁciency virus.
a Not included in the deﬁnition, but considered a risk factor for multidrug-resistant pathogens.
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for MDR organisms, and increase the cost of healthcare.21 According
to the 2005 ATS/IDSA guidelines, HCAP includes any patient
presenting with pneumonia with one of the following features:
(1) hospitalization for two or more days in an acute care facility
within 90 days of infection, (2) patients from a nursing home or long-
term care facility (LTCF), (3) patients who attended a hospital or
hemodialysis clinic, and (4) those who received intravenous
antibiotic therapy, chemotherapy, or wound care within 30 days
of infection.3 These deﬁnitions have been incorporated by different
authors in clinical studies (Table 1). Most studies considered prior
hospitalization of at least 2 days in the 90 days preceding
hospitalization as an important risk factor (Table 2).12,15,16However,Table 2
Percentage of patients included in four criteria for HCAP (including overlapping cases)
Study [Ref.] Previous hospitalization Hemodia
Kollef et al. 2005 Not reported 11.6%a
988 patients (median age 73 years)
Micek et al. 2007 93.3% 10% 
431 patients (mean age 59.8 years)
Carratala` et al. 2007 43.7% 31.7% 
126 patients (mean age 69.5 years)
Webster et al. 2007 25% 0% 
28 patients (mean age 67.8 years)
Shorr et al. 2008 63% 6.7% 
639 patients (mean age 59.7 years)
Venditti et al. 2009 80% 3.3% 
90 patients (mean age 62.2 years)
Shindo et al. 2009 39% 7.1% 
141 patients (mean age 81.3 years)
Rello et al. 2010 56.8% 2.3% 
44 patientsc (median age 77 years)
Schreiber et al. 2008 22.1% 15.3% 
190 patients (mean age 60.9 years)
Cecere et al. 2010 24% 5% 
164 patients (mean age 46.1 years)
HCAP, healthcare-associated pneumonia; LTCF, long-term care facility.
a Patients with a history of chronic renal disease, not speciﬁed if undergoing hemod
b Long-term corticosteroid use.
c Only cases of pneumococcal HCAP.other authors have found it useful to expand this interval to 180–
360 days.6,10 All HCAP studies are concordant in considering
residence in a nursing home or in a LTCF and hemodialysis as risk
factors for HCAP, and most authors also included immunosuppres-
sion as a potential risk factor.6,10–12,14,16,18,19
4. Role of MDR pathogens in patients with risk factors for HCAP
4.1. Previous hospitalization and previous antibiotic treatment
Exposure to the hospital environment creates an opportunity
for pathogens not commonly present in the community to colonize
the upper respiratory and gastrointestinal tracts of patients. Thislysis Residence in a nursing home or LTCF Immunosuppression
49.6% 23.2%
28.1% 39.7%
25.4% 11.9%b
44% 31%
18.9 30%
10% 6.7%
61% 9.2%
38.5% 18.2%
26.8% 22.1%
30% 58%
ialysis therapy.
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antibiotics, often for prolonged periods of time, which select for
drug-resistant pathogens.22
Colonization and subsequent microaspiration of MDR patho-
gens acquired during healthcare exposure has been proposed as
the mechanism for the occurrence of HCAP attributed to MDR
pathogens.5 Admission to a room previously occupied by a
methicillin-resistant Staphylococcus aureus (MRSA)-positive pa-
tient or a vancomycin-resistant Enterococcus (VRE)-positive
patient signiﬁcantly increased the odds of acquisition of MRSA
and VRE.23 However, a prospective study that evaluated 1100
patients with MRSA infections found that 131 (12%) were
community-associated without any identiﬁable healthcare expo-
sure (i.e., no history of hospitalization, surgery, dialysis, or
residence in a LTCF within the previous 12 months).24 Prolonged
MRSA carriage does not appear to be rare, with 40% of patients who
became colonized by MRSA during hospitalization remaining
colonized for a median time of 8.5 months.25 A retrospective
cohort study from Switzerland found that the median time to
clearance of MRSA colonization was 7.4 months, and that
independent determinants for longer carriage duration were the
receipt of antibiotics, use of an indwelling vascular device,
presence of a skin lesion, immunosuppressive therapy, and
hemodialysis.26 New MRSA carriers also have a high risk of
developing a sterile-site MRSA infection in the year following
acquisition.27,28
Hospitalized patients can also be colonized de novo by MDR
Gram-negative bacilli. It has been estimated that 8% of patients
newly admitted to general medical wards become carriers of
extended-spectrum beta-lactamase (ESBL)-producing Enterobac-
teriaceae during their hospitalization.29 Risk factors for rectal
carriage of ESBL-producing Enterobacteriaceae include female sex
(odds ratio (OR) 11), nursing home residence (OR 6.9), recent
antibiotic treatment (OR 9.8), and concomitant nasal carriage of
MRSA and/or ESBL-producing Enterobacteriaceae (OR 5.8).29 Zahar
et al. found that the median duration of ESBL carriage was
132 days, and that patients readmitted between 6 months and
1 year after their last positive culture were still positive 50% of the
time.30
To date, a limited number of good quality studies have reported
on the relationship between prescribing antibiotics and prevalence
of antibiotic resistance for individuals treated in the primary care
setting.31 Very recently, Costelloe and co-workers systematically
reviewed the literature and performed a meta-analysis describing
the occurrence of antibiotic resistance in individuals prescribed
antibiotics in primary care.32 Among patients with respiratory
infections, there was evidence of an association between
antibiotics and resistance between 0 and 1 month (with an OR
of 2.1, 95% conﬁdence interval (CI) 1.0–4.2), 0 and 2 months
(pooled OR 2.4, 95% CI 1.4–3.9), and 0 and 12 months (pooled OR
2.4, 95% CI 1.3–4.5). Thus the effects of previous antibiotic
prescription on resistance emergence were strongly detectable for
up to 12 months after exposure, even in primary care.
Shorr et al. examined the individual risk factors for HCAP in an
attempt to identify their relative importance for the presence of
infection attributed to antibiotic-resistant bacteria.14 Overall, 639
patients were included in their study, and drug-resistant patho-
gens were found in 289 (45.2%) patients. Multivariate analysis
identiﬁed recent hospitalization (OR 4.2), residing in a nursing
home (OR 2.7), undergoing hemodialysis (OR 2.11), and admission
to an intensive care unit (ICU) (OR 1.62) as independent risk factors
for antibiotic-resistant infection. Similarly, a prospective observa-
tional study evaluating the accuracy of the ATS/IDSA criteria in
predicting infection or colonization with MDR bacteria at the time
of ICU admission found recent hospitalization (OR 3.9), prior
antimicrobial treatment (OR 2.3), and residence in a nursing home(OR 2.0) as independent predictors of infection with MDR
bacteria.33 These criteria had high sensitivity (89%) and negative
predictive value (96%), but low speciﬁcity (39%) and positive
predictive value (18%) for the prediction of MDR bacteria.33
Another retrospective study of 190 patients with nosocomial
pneumonia and respiratory failure analyzed the factors associated
with respiratory infection due to MDR bacteria.34 The presence of
antibiotic-resistant infection was more common in patients
meeting the HCAP deﬁnition (78% vs. 44%; p = 0.001). Multivariate
analysis identiﬁed immunosuppression (adjusted OR 4.85;
p < 0.001), LTCF admission (adjusted OR 2.36; p = 0.029), and
prior broad-spectrum antibiotics (adjusted OR 2.12; p = 0.099) in
the previous 30 days as independent risk factors for infection with
an antibiotic-resistant pathogen.34
4.2. Residence in a long-term care facility
Infections occurring in LTCFs are likely to have a signiﬁcant
impact on the mortality rate of residents.35 Older patients living in
LTCFs frequently have a deterioration of consciousness, and are
likely to aspirate oropharyngeal contents at night, usually without
documentation of its occurrence. A previous study analyzing
swallowing function reported a high incidence of aspiration
pneumonia among hospitalized patients with a history of prior
hospitalization of at least 2 days in the preceding 90 days or a stay
at a nursing home or extended care facility.36 Patients with
dysphagia and feeding tubes are also at high risk of silent
aspiration.3
There is evidence that residents of LTCFs are an important
reservoir of MDR pathogens and contribute to the inﬂux of MDR
bacteria into the hospital setting.37–39 Studies performed more
than 10 years ago in Veterans’ Affairs facilities in the USA showed a
high prevalence of MRSA colonization among residents, with rates
ranging from 13% to 35%.40,41 Major sites of colonization were
nares and wounds, and, in some institutions, up to 80% of decubitus
ulcers were colonized.40,41 In addition to studies from the USA,
European studies have evaluated the prevalence of MRSA
colonization in LTCFs, describing ranges between 8.6% and 22%
of inhabitants.42–46 MRSA colonization in LTCFs may have less
severe consequences than in acute-care hospitals. MRSA carriers
have a 30–60% risk of developing an infection during hospitaliza-
tion in an acute-care hospital, whereas this risk is only 5–10%
during a stay at a LTCF.47Elderly residents living in LTCFs are also at
high risk of colonization and infection with MDR Gram-negative
bacteria. A cross-sectional study performed in a 648-bed LTCF in
Boston, Massachusetts, USA, showed that 51% of residents were
colonized by MDR Gram-negative bacilli, the most common
species being Providencia stuartii, Morganella morganii, Escherichia
coli, Proteus mirabilis, Klebsiella pneumoniae, and Enterobacter spp.48
The prevalence of Gram-negative bacteria was signiﬁcantly higher
than the prevalence of VRE and MRSA, and a diagnosis of advanced
dementia and non-ambulatory status were signiﬁcant risk factors
for harboring these pathogens.48 Subsequent studies have
conﬁrmed these observations.49–51
Some investigators examining pneumonia occurring among
residents of LTCFs have proposed the term ‘nursing home-acquired
pneumonia’ (NHAP). El-Solh et al. conducted a study of 104 elderly
patients (aged 75 years; 55% from the community and 45% from
nursing homes) admitted to the ICU with severe pneumonia
necessitating mechanical ventilation.52 The distribution of infec-
tion-associated pathogens in patients admitted from nursing
homes was signiﬁcantly different from that of patients admitted
from the community. Among patients with CAP, Streptococcus
pneumoniae (14%) was the predominant pathogen, whereas among
those with NHAP the most common isolated pathogen was
Staphylococcus aureus (29%).52 In another study, El-Solh et al. found
Fig. 1. Mortality rates (%) for community-acquired pneumonia (CAP) and
healthcare-associated pneumonia (HCAP) in different published studies.
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6 months and an Activities of Daily Living (ADL) score 12.5
showed a 90% probability of having NHAP caused by drug-resistant
pathogens.53
Three prospective, randomized trials of therapy for NHAP have
provided some insight on HCAP. Unfortunately, these studies
included a large proportion of patients not requiring hospitaliza-
tion, receiving oral or parenteral monotherapies such as levo-
ﬂoxacin,54 cefepime,55 or ertapenem56 (in the latter case patients
with pseudomonal risk or severe illness were excluded). Bacterio-
logic data were not available and patients with mild NHAP had
good clinical outcomes when treated with antimicrobial mono-
therapy.54–56 This differed from patients with NHAP included in a
multicenter prospective study conducted in Germany, who were
characterized by a more than four-fold increased mortality rate
compared with elderly patients living in the community (28.8% vs.
6.9%).57 Interestingly, a higher incidence of Gram-negative
infections was observed in the NHAP group (18.8% vs. 5.5%), and
39.7% of NHAP patients had a change in their original antibiotics
(15.6% due to sequential therapy, 14.1% due to ineffectiveness, 5.5%
de-escalation, and 2.0% due to resistance).57
More recently, Polverino et al. published data on 150
consecutive cases of NHAP observed over a 10-year period
(1997–2007).58 NHAP patients appeared similar to patients with
HAP in terms of age, functional status, and co-morbidities, but the
in-hospital mortality was surprisingly low (8.7%).58 Despite the
absence of signiﬁcant differences between NHAP and CAP in terms
of microbial etiology, the authors observed that among the 32
NHAP patients whose pathogens had antimicrobial susceptibility
testing performed, initial antibiotic therapy was inappropriate in
12 (38%) patients infected with antibiotic-resistant pathogens.
More importantly, the isolation of unusual microorganisms such as
Gram-negative bacilli or MRSA was associated with a considerable
increase in the mortality risk (OR 16.4, 95% CI 2.1–128.9;
p < 0.008).58
4.3. Hemodialysis and patients receiving home intravenous therapy
The population of patients who undergo chronic hemodialysis
(CHD) has contributed substantially to the emergence and
dissemination of antimicrobial-resistant pathogens. Two essential
factors have contributed to this: (1) patient-to-patient transmis-
sion of pathogens, and (2) the selective pressure from antibiotic
exposure. The dialysis unit and its population provide an ideal
setting for cross-transmission of pathogens, because regular
hemodialysis is required three times per week in a closed setting
and because healthcare workers provide concurrent care to
multiple patients. Additionally, patients undergoing CHD require
one or two hospital admissions per year.59 During these
hospitalizations, patients are frequently exposed to the ICU,
invasive procedures, and antibiotics.60
VRE and MRSA are among the antimicrobial-resistant bacteria
that have been intensely investigated in this patient population.
The prevalence of MDR Gram-positive pathogens is variable. A
cross-sectional analysis of 198 hemodialysis outpatients showed
low MRSA (5.6%) and VRE (3.14%) colonization rates.61 However, a
5-year surveillance study on patients undergoing continuous
peritoneal dialysis (CPD) found that 76% of patients had at least one
nares and/or central venous catheter (CVC) exit culture positive for
MRSA; out of these, 44% were persistent carriers, and this status
was associated with a three-fold higher risk for CPD-related
infections and six-fold higher rates of vancomycin consumption
compared to those for the intermittent carriers.62 Lu et al. found
that pulmonary disease (OR 4.8), recent admission to a hospital
(OR 2.7), and recent antibiotic usage (OR 2.3) were signiﬁcantly
associated with MRSA carriage among patients undergoingdialysis, their families, and healthcare workers in the dialysis
unit.63 More recently, Mermel et al., in a prospective, multicenter
study, identiﬁed MRSA colonization in 20% of elderly residents of
LTCFs, 16% of HIV-infected outpatients, 15% of outpatients
receiving hemodialysis, 14% of inpatients receiving hemodialysis,
and 6% of others.64
Hemodialysis patients can also be at risk for colonization and
infection with MDR Gram-negative bacteria. A prospective cohort
study of an outpatient hemodialysis unit showed that 28% of
patients were colonized with one or more MDR bacteria. MDR
Gram-negative bacilli were recovered from 16% of patients at
enrollment, compared with 13% and 5% of patients with VRE and
MRSA, respectively.65 The subgroup of chronic hemodialysis
patients who were at highest risk for harboring MDR Gram-
negative bacilli at enrollment were patients who resided in a LTCF
and those with antibiotic exposure in the previous 3 months.65
Colonization by MDR pathogens in hemodialysis patients is a
well recognized risk factor for bloodstream infections, but there
are few studies on pneumonia in this category of patients.66
Berman and co-workers reviewed the infections occurring in 433
patients undergoing chronic hemodialysis at a single hospital-
based dialysis program over a 9-year period.67 Pneumonia
accounted for 13% of all infections and was the third most
frequent cause of infection. The most common causative patho-
gens for pneumonia were S. aureus (MRSA was involved in 75% of
cases), Pseudomonas aeruginosa, Klebsiella species, Enterobacter
species, and E. coli. Traditional community pathogens such as
Moraxella species, Haemophilus inﬂuenzae, and S. pneumoniae
accounted only for 15% of cases (28 out of 186 episodes).67
4.4. Outcome of HCAP in the published studies
Fig. 1 describes the mortality rates for CAP and HCAP observed
in the different studies comparing these conditions. Despite some
differences regarding the inclusion criteria described above, all
studies observed statistically signiﬁcant differences in terms of
mortality between patients with CAP and HCAP. Some authors
attributed this increased mortality to differences existing in terms
of median age or presence of co-morbidities,16 but other studies
conﬁrmed that patients with HCAP had a worse prognosis
independent of differences in age, co-morbidities, or immunosup-
pression.6 A critical disparity appears to be the greater adminis-
tration of inappropriate initial antimicrobial therapy in patients
with HCAP compared to those with CAP, as a result of a higher
incidence of infection with antibiotic-resistant pathogens among
patients with HCAP.10,12–15
Fig. 2 describes the odds ratio (OR) for mortality in patients with
HCAP treated with inappropriate empiric antibiotic therapy. These
data indicate that patients given inappropriate initial antimicrobial
therapy are more likely to die during hospitalization. The
Fig. 2. Odds ratios for mortality in patients with healthcare-associated pneumonia (HCAP) treated with inappropriate antimicrobial therapy or with antibiotics not
recommended in the ATS/IDSA guidelines.
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patients with HCAP are most often MRSA, P. aeruginosa or other
non-fermenting Gram-negative rods, and antibiotic-resistant
Enterobacteriaceae.6,10 In a Japanese study, HCAP patients with
potentially drug-resistant pathogens (including MRSA, P. aerugi-
nosa, and ESBL-producing Enterobacteriaceae) had a risk ratio of
14.0 (95% CI 4.5–43.6; p < 0.001) with respect to inappropriate
initial antibiotic treatment.15
5. Conclusions
The body of evidence presented in this review provides support
for the deﬁnition of HCAP, which represents a category of
pneumonia epidemiologically and microbiologically distinct from
CAP.68 Physicians should correctly identify patients with HCAP in
order to provide optimal clinical management. As recommended
by the ATS/IDSA nosocomial pneumonia guidelines, an empirical
broad-spectrum antibiotic regimen is suggested in most patients
with serious HCAP infection, especially those individuals requiring
intensive care and mechanical ventilation.3 However, the selection
of initial empiric therapy must be patient-oriented and based on
the local patterns of antibiotic resistance.
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